BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that its Bio-Medical division has successfully developed a new diagnostics kit to detect COVID-19. Additionally, this kit has undergone testing by several central laboratories and hospitals that have now verified its ability to diagnose COVID-19.
The Group has commenced production of the kit at its Adaltis facility in Rome. BATM is working with academic and research institutions, mainly in Europe, to progress the kit to make it at a price point suitable for large scale production. The kit, which supports all the Centers for Disease Control and Prevention (CDC) recommendations, has already received interest from customers in several countries.
In addition, COVID-19 will be included within the Ador suite of testing kits as part of its travel panels. Laboratory bench tests are expected to commence imminently.
Dr Zvi Marom, Chief Executive Officer of BATM, said:
“We believe that the strategy we adopted in our Bio-Medical division is proving to be correct, especially in light of the current COVID-19 outbreak. We are able now to quickly provide diagnostic kits for any new pathogen that appears.
“Furthermore, we have already received extremely positive feedback and significant interest from several leading medical institutions that have started testing the first panel of Ador’s NATlab solution and adding COVID-19 will greatly strengthen its appeal and value.”